Previous 10 | Next 10 |
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the pricing of an underwritten public offering with gross proceeds of approximately $150.0 million. Viridian i...
2024-01-17 16:17:04 ET More on Viridian Therapeutics Viridian Therapeutics: Disconnect Between Fundamentals And Share Price In 2023 Viridian: Market May Be Wrong In Its Disapproval Viridian Therapeutics GAAP EPS of -$1.09 beats by $0.08, revenue of $0.07M misses by $...
- VRDN-001 topline clinical results for THRIVE and THRIVE-2 on track for mid-2024 and year-end 2024 in patients with active and chronic thyroid eye disease (TED), respectively - - Subcutaneous VRDN-003 pivotal study in TED anticipated to start in mid-2024, pending alignment with regulator...
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that its President and Chief Executive Officer, Steve Mahoney, will present an overview of the company alo...
2023-12-29 11:23:28 ET Summary Shares of Viridian Therapeutics underperformed this year. Negative biotech sentiment was partly to blame, as well as Tepezza's Y/Y net sales declines, and some internal turmoil with two CEO changes. These events overshadowed many positive develop...
2023-12-29 08:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
- VRDN-003 clinical data exceeded expectations with extended half-life of 40-50 days, 4-5x longer than VRDN-001, supporting a potential best-in-class, low-volume, less frequent, self-administered subcutaneous therapy for thyroid eye disease (TED) - - Data support VRDN-003 dosing as infreq...
2023-12-12 08:00:00 ET Summary Viridian Therapeutics, Inc. stock has been on a downward trend since announcing complex data in July. The market may be wrong in its assessment. However, I have no big conviction as to market success, only trial success. I did well with...
2023-11-30 16:50:45 ET More on Viridian Therapeutics Viridian Therapeutics: Mixed Bag, Not Eye-Catching Enough Viridian Therapeutics GAAP EPS of -$1.09 beats by $0.08, revenue of $0.07M misses by $0.03M Viridian Therapeutics appoints Stephen Mahoney as CEO Se...
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Confe...
News, Short Squeeze, Breakout and More Instantly...
Viridian Therapeutics Inc Com Company Name:
VRDN Stock Symbol:
NASDAQ Market:
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will participate in the following upcoming investor conferences in May: 202...
- THRIVE VRDN-001 global phase 3 clinical trial in active thyroid eye disease (TED) completed and exceeded its target for enrollment in March 2024; topline readout expected in September 2024 - - THRIVE-2 VRDN-001 global phase 3 clinical trial for patients with chronic TED remains on track...
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced it will host a webcast and conference call on Wednesday, May 8 at 8:00 a.m. ET to discuss its first quarter 20...